galegenimab   Click here for help

GtoPdb Ligand ID: 11759

Synonyms: 15H6v4.D221 | FHTR2163 | RG-6147 | RG6147 | RO-7171009 | RO7171009
Compound class: Antibody
Comment: Galegenimab is the INN that has been assigned to Genentech's anti-HTRA1 (HtrA serine peptidase 1) Fab antibody [6]. The antibody and its use are claimed in patent WO2017075212A1 [3]. HTRA1 is a serine protease whose substrates include transforming growth factor β [1,5], fibronectin, amyloid precursor protein [2] and Dickkop-related protein 3 (DKK3) [4]. Genetic polymorphisms in the HTRA1 gene are associated with an increased risk of developing neovascular age-related macular degeneration (and geographic atrophy) and with disease progression. Thus inhibition of HTRA1 proteolytic activity is being investigated for this ocular indication.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Galegenimab (formerly RG6147 and RO7171009) has advanced to clinical evaluation, to determine efficacy as a treatment for geographic atropy secondary to age-related macular degeneration.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03295877 Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) Phase 1 Interventional Genentech, Inc. 4
NCT04607148 A Study Assessing the Long-Term Safety and Tolerability of RG6147 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration Phase 2 Interventional Genentech, Inc.
NCT03972709 A Study Assessing the Safety, Tolerability, and Efficacy of RG6147 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) Phase 2 Interventional Genentech, Inc.